Search | Clinical Trials Finder

Conditions: Hepatitis C, Chronic Kidney Disease
Interventions: Sofosbuvir/Ledipasvir FDC; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions: Behavioral Intervention, Educational Intervention, Questionnaire Administration; Behavioral · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Multiple Sclerosis
Interventions: Avonex/Zocor; Drug
Lead sponsor: University of North Carolina; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Ewings Sarcoma, Chemotherapy Induced Thrombocytopenia
Interventions: Romiplostim (AMG-531); Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Year and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Phoenix, Arizona • Cincinnati, Ohio

Conditions: Overactive Bladder
Interventions: TENS; Device
Lead sponsor: Theranova, L.L.C.; Industry
Eligibility: 55 Years to 100 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Acute Stroke
Interventions: Non-invasive electromagnetic stimulation for acute stroke treatment; Device
Lead sponsor: Nervive, Inc.; Industry
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Opioid-use Disorder
Interventions: Patient Navigation, Buprenorphine; Behavioral · Drug
Lead sponsor: Friends Research Institute, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Breast Carcinoma, Cancer Survivor, Cognitive Side Effects of Cancer Therapy, Malignant Female Reproductive System Neoplasm
Interventions: Cognitive Intervention, Educational Intervention, Functional Magnetic Resonance Imaging, Memory Intervention, Quality-of-Life Assessment, Questionnaire Administration; Other · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 21 Years to 90 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Parkinson's Disease
Interventions: AAV2-GDNF; Biological
Lead sponsor: Brain Neurotherapy Bio, Inc.; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: Irvine, California • San Francisco, California • Columbus, Ohio

Conditions: Written Exposure Therapy, Imaginal Exposure Therapy
Interventions: Written Exposure Therapy, Imaginal Exposure Therapy; Behavioral
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 18 Years to 99 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: Emtricitabine/ tenofovir disoproxil fumarate, Lopinavir/Ritonavir; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 25
States / cities: San Diego, California • San Francisco, California • Torrance, California + 16 more

Conditions: Invasive Ductal Breast Cancer, Carcinoma Breast Stage I
Interventions: Intraoperative Electron Radiotherapy; Radiation
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years to 95 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Elevated Blood Pressure, Pregnancy Induced Hypertension
Interventions: Nifedipine, Labetalol; Drug
Lead sponsor: Marshall University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Huntington, West Virginia

Conditions: Pulmonary Embolism
Interventions: Rivaroxaban, Standard-of-care; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 50
States / cities: Montgomery, Alabama • Chandler, Arizona • Phoenix, Arizona + 47 more

Conditions: HIV Infections
Interventions: Patients elected to take licensed drugs. The vaccine was not provided for evaluation, multiple licensed drugs not randomized, multiple licensed antiretroviral drugs; not randomized, Intended vaccine not provided, Licensed drugs provided, but were not investigated; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Grief
Interventions: Accelerated Resolution Therapy, Information and Support; Behavioral · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 60 Years and older
Enrollment: 440 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Phoenix, Arizona • Clearwater, Florida • Jacksonville, Florida + 1 more

Conditions: Breast Cancer
Interventions: Atezolizumab, Placebo, Doxorubicin, Cyclophosphamide, Paclitaxel, Trastuzumab, Pertuzumab, Trastuzumab Emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Kansas City, Missouri • New York, New York • Nashville, Tennessee

Conditions: Presbyopia
Interventions: Aceclidine+tropicamide combination, Aceclidine, Vehicle; Drug
Lead sponsor: LENZ Therapeutics, Inc; Other
Eligibility: 48 Years to 64 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: ALL, Childhood, Behavior, Health
Interventions: NOURISH-ALL; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 2 Years to 12 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Kansas City, Kansas • Kansas City, Missouri

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Nicotinamide, Placebo Comparator; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 50 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Irvine, California • Los Angeles, California

Conditions: Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder
Interventions: MIP Protocol; Behavioral
Lead sponsor: The National Center on Addiction and Substance Abuse at Columbia University; Other
Eligibility: 13 Years to 17 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Staphylococcus Aureus Bacteremia
Interventions: Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA, Single Agent IV Antibiotic Therapy - MSSA; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Urinary Incontinence
Interventions: Urodynamic testing with and without pudendal nerve stimulation; Diagnostic Test
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 2
States / cities: Royal Oak, Michigan

Conditions: Acute Lymphoblastic Leukemia
Interventions: Inotuzumab ozogamicin, Methotrexate, Hydrocortisone, Cytarabine, Diphenhydramine, Acetaminophen, Methylprednisolone; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: San Diego, California • Memphis, Tennessee

Search by objective public record fields.

Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)

Financial Health Educational Program for Increasing Financial Literacy Among Underserved Communities in Western New York

EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis

Single Arm Romiplostim to Prevent CIT

Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home

Early Feasibility Study of the Nervive VitalFlow Stimulation for Acute Ischemic Stroke Patients

Opioid Use Disorder Treatment Linkage at Strategic Touchpoints Using Buprenorphine

Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms

GDNF Gene Therapy for Parkinson's Disease

Written Versus Verbal Brief Cognitive Behavioral Exposure Therapy

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV

Lumpectomy Followed By Intraoperative Electron Radiation Therapy (IOERT)

Treatment of Elevated Blood Pressures in Early Pregnancy

A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised

Accelerated Resolution Therapy for Early Maladaptive Grief

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

Healthy Weight Intervention Families During ALL Treatment: NOURISH-ALL

Nicotinamide as an Early Alzheimer's Disease Treatment

Medication Integration in Treatment of Comorbid Adolescent Substance Users/Attention Deficit Hyperactivity Disorder

Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?

Acute Pudendal Nerve Stimulation On Leak Point Pressure In Women Urodynamic Early Feasibility Study

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia